Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer

The data presented herein are supplementary to our published primary article “A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer”[1]. The exploratory analysis evaluated the impac...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, Bradley J., Herzog, Thomas J., Wang, George, Triantos, Spyros, Maul, Scott, Knoblauch, Roland, McGowan, Tracy, Shalaby, Waleed S.W., Coleman, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Medicine and Dentistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178483/
https://www.ncbi.nlm.nih.gov/pubmed/32346557
http://dx.doi.org/10.1016/j.dib.2020.105465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178483/
https://www.ncbi.nlm.nih.gov/pubmed/32346557
http://dx.doi.org/10.1016/j.dib.2020.105465

Ejemplares similares